soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 The Role of Glucagon-Like Peptide-1

Loose skin depends on the amount of weight lost, age, genetics, and skin elasticity

Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

Dosage and frequency determined based on individual condition severity

Less than half do it in a way that protects their physiology

Novo Nordisk holds patents on semaglutide that extend through approximately 2032, preventing generic manufacturers from producing equivalent versions

These results indicated that the administration of 2APB effectively inhibited the transmission of oxidative stress molecules by hepatocyte GJs and impacted oxidative stress in the liver